

Form PTO-1449 (modified)		Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Donald W. KUFE Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents	Foreign Patent Documents	Other Art See Page 1-2	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C295	Bitko <i>et al.</i> , "Inhibition of respiratory viruses by nasally administered siRNA," <i>Nature Medicine</i> , 11:50-55, 2005.
	C296	Burncrot <i>et al.</i> , "RNAi therapeutics: a potential new class of pharmaceutical drugs," <i>Nature Chemical Biology</i> , 2:711-719, 2006.
	C297	Dykhhoorn <i>et al.</i> , "The silent treatment: siRNAs as small molecule drugs," <i>Gene Therapy</i> , 13:541-552, 2006.
	C298	Geisbert <i>et al.</i> , "Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference," <i>J. Infect. Dis.</i> , 193:1650-1657, 2006.
	C299	Grzelinski <i>et al.</i> , "RNA interference-mediated gene silencing of pleiotrophin through polythymine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts," <i>Human Gene Therapy</i> , 17:751-766, 2006.
	C300	Kim <i>et al.</i> , "Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma," <i>Molecular Therapy</i> , 14:343-350, 2006.
	C301	Li <i>et al.</i> , "Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque," <i>Nature Medicine</i> , 11:944-951, 2005.
	C302	Luo <i>et al.</i> , "An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons," <i>Molecular Pain</i> , 1:29, 2005.

70675409.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

Form PTO-1449 (modified)		Atty. Docket No.: <b>GENU:006US</b>	Serial No.: <b>10/598,295</b>
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT		Applicant: <b>Donald W. KUFE</b> <b>Surender KHARBANDA</b>	
(Use several sheets if necessary)		Filing Date: <b>April 5, 2007</b>	Group: <b>1635</b>
U.S. Patent Documents	Foreign Patent Documents	Other Art See Page 1-2	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C303	Makimura <i>et al.</i> , "Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake," <i>BMC Neuroscience</i> , 3:18, 2002.
	C304	Minakuchi <i>et al.</i> , "Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo," <i>Nucleic Acids Research</i> , 32:e109, 2004.
	C305	Nakamura <i>et al.</i> , "RNA interference targeting transforming growth factor- $\beta$ type II receptor suppresses ocular inflammation and fibrosis," <i>Molecular Vision</i> , 10:703-11, 2004.
	C306	Niu <i>et al.</i> , "Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo," <i>Int. J. Gynecol. Cancer</i> , 16:743-751, 2006.
	C307	Palliser <i>et al.</i> , "An siRNA-based microbicide protects mice from lethal herpes simplex 2 infection," <i>Nature</i> , 89-94, 2006.
	C308	Reich <i>et al.</i> , "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9:210-6, 2003.
	C309	Ren <i>et al.</i> , "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents," <i>Cancer Cell</i> , 5:163-175, 2004.
	C310	Schiffelers <i>et al.</i> , "Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle," <i>Nucleic Acids Research</i> , 32:e149, 2004.
	C311	Shen <i>et al.</i> , "Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1," <i>Gene Therapy</i> , 13:225-234, 2006.
	C312	Soutschek <i>et al.</i> , "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> , 432:173-178, 2004.
	C313	Takei <i>et al.</i> , "A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics," <i>Cancer Research</i> , 64:3365-3370, 2004.
	C314	Thakker <i>et al.</i> , "siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain," <i>Molecular Psychiatry</i> , 10:782-789, 2005.
	C315	Urban-Klein <i>et al.</i> , "RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo," <i>Gene Therapy</i> , 12:461-466, 2005.
	C316	Zimmerman <i>et al.</i> , "RNAi-mediated gene silencing in non-human primates," <i>Nature</i> , 441:111-114, 2006.

70675409.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.